We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+58.72%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.79B
AUM Growth
+$202M
Cap. Flow
-$337M
Cap. Flow %
-18.85%
Top 10 Hldgs %
65.26%
Holding
83
New
17
Increased
15
Reduced
17
Closed
21

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$37.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.1M
3
INCY icon
Incyte
INCY
+$16.8M
4
SYK icon
Stryker
SYK
+$16.7M
5
KURA icon
Kura Oncology
KURA
+$16.4M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$77.4M
2
DXCM icon
DexCom
DXCM
+$54.2M
3
IDXX icon
Idexx Laboratories
IDXX
+$34.1M
4
AZN icon
AstraZeneca
AZN
+$33.3M
5
ELAN icon
Elanco Animal Health
ELAN
+$27.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Consumer Staples 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTXW
51
DELISTED
Immatics N.V. Warrants
IMTXW
$930K 0.05%
318,372
-524
-0.2% -$1.33K
IMA
52
ImageneBio Inc
IMA
$63.2M
$716K 0.04%
30,290
+20,647
+214% +$673K
PDSB icon
53
PDS Biotechnology
PDSB
$38.7M
$709K 0.04%
142,635
– –
PEN icon
54
Penumbra
PEN
$12.6B
$503K 0.03%
+2,000
New +$442K
GRTX
55
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$448K 0.03%
3,083,712
– –
FULC icon
56
Fulcrum Therapeutics
FULC
$249M
$193K 0.01%
+28,600
New +$127K
PEPG icon
57
PepGen
PEPG
$131M
$157K 0.01%
+23,038
New +$126K
ESTA icon
58
Establishment Labs
ESTA
$2.71B
$79K ﹤0.01%
+3,052
New +$89.4K
SPRB
59
Spruce Biosciences
SPRB
$116M
$66.7K ﹤0.01%
304
-470
-61% -$54.3K
SLNO
60
DELISTED
Soleno Therapeutics
SLNO
$48.3K ﹤0.01%
+1,200
New +$34.1K
VIR icon
61
Vir Biotechnology
VIR
$1.48B
$45.2K ﹤0.01%
+4,495
New +$41.1K
ALKS icon
62
Alkermes
ALKS
$8.79B
– –
-537,464
Closed -$15.1M
AXSM icon
63
Axsome Therapeutics
AXSM
$12.3B
– –
-80,368
Closed -$5.62M
CLDX icon
64
PUT
Celldex Therapeutics
CLDX
$2.8B
– –
-200,000
Closed -$5.5M
CRSP icon
65
PUT
CRISPR Therapeutics
CRSP
$4.6B
– –
-200,000
Closed -$9.08M
CYTK icon
66
PUT
Cytokinetics
CYTK
$10.9B
– –
-500,000
Closed -$14.7M
EXEL icon
67
Exelixis
EXEL
$14B
– –
-830,764
Closed -$18.2M
EXEL icon
68
PUT
Exelixis
EXEL
$14B
– –
-912,600
Closed -$19.9M
IDXX icon
69
Idexx Laboratories
IDXX
$43.9B
– –
-77,881
Closed -$34.1M
IWM icon
70
PUT
iShares Russell 2000 ETF
IWM
$80.3B
– –
-225,000
Closed -$39.8M
QQQ icon
71
Invesco QQQ Trust
QQQ
$449B
– –
-50,000
Closed -$17.9M
REPL icon
72
CALL
Replimune Group
REPL
$724M
– –
-250,000
Closed -$4.28M
REPL icon
73
Replimune Group
REPL
$724M
– –
-503,844
Closed -$8.62M
REPL icon
74
PUT
Replimune Group
REPL
$724M
– –
-313,100
Closed -$5.36M
SNDX icon
75
CALL
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-600,000
Closed -$8.71M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2023 Portfolio in Review

As of Q4 2023, Sofinnova Investments held 83 positions worth $1.79B, up 13% from $1.59B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $337M in Q4 2023, closing 21 positions and reducing 17 holdings. Its most notable exit was Idexx Laboratories, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $37.6M.

  • Sofinnova Investments's largest Q4 2023 buy was Eli Lilly: 64,525 shares worth $37.6M.
  • Sofinnova Investments added most to Stryker in Q4 2023, an estimated $16.7M increase.
  • Sofinnova Investments's biggest Q4 2023 reduction was Natera, cutting an estimated $77.4M.
  • Sofinnova Investments fully exited Idexx Laboratories in Q4 2023, selling an estimated $34.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.79B portfolio in Q4 2023.
  • Sofinnova Investments opened 17 new positions and closed 21 in Q4 2023.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $1.79B.

Based on Sofinnova Investments's 13F filing for Q4 2023, filed 13 Feb 2024.